Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933160 | 0.89 | CHRM1 (0.76) | MAPTCHRM1LMNAALDH1A1POLB | |
| SCHEMBL2937692 | 0.89 | MAPT (0.62) | MAPTCHRM1LMNAALDH1A1TP53 | |
| SCHEMBL13762897 | 0.87 | CHRM1 (0.77) | MAPTCHRM1LMNAALDH1A1TP53 | |
| SCHEMBL2931231 | 0.87 | MAPT (0.68) | MAPTCHRM1LMNAALDH1A1TP53 | |
| SCHEMBL2930243 | 0.86 | LMNA (0.71) | CHRM1LMNATP53CNR2CNR1 | |
| SCHEMBL2937922 | 0.85 | LMNA (0.57) | CHRM1LMNAALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL2937596 | 0.83 | LMNA (0.55) | CHRM1LMNATP53CNR2 | |
| SCHEMBL13762896 | 0.82 | MAPT (0.69) | MAPTCHRM1LMNAALDH1A1TP53 | |
| SCHEMBL12707380 | 0.81 | MAPT (0.68) | MAPTCHRM1LMNAALDH1A1TP53 | |
| SCHEMBL2932156 | 0.81 | TP53 (0.65) | MAPTCHRM1LMNATP53CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776883-B2 | Quinolin-4-ones as inhibitors of retroviral integrase for the treatment of HIV, AIDS and AIDS related complex (ARC) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-08-17 | — | — | US | disclosed |
| US-20070219242-A1 | Quinolin-4-Ones as Inhibitors of Retroviral Integrase for the Treatment of Hiv, Aids and Aids Related Complex (Arc) | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219242-A1 | Quinolin-4-Ones as Inhibitors of Retroviral Integrase for the Treatment of Hiv, Aids and Aids Related Complex (Arc) | QTRT1, QTRT2, CTCF | MAPT 1583/4885CHRM1 4089/4885LMNA 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.